ZMYND8

Across TCGA pan-cancer cohorts, ZMYND8 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ZMYND8’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ZMYND8 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZMYND8 is over-expressed in tumor.

LSCC, LUAD, and COAD are the cancer types where ZMYND8 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZMYND8 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.624	<.001	9	view →
LUAD	Male	III,IV	+0.568	<.001	9	view →
COAD	Female	II,III,IV	+0.395	<.001	9	view →
HNSC	Male	IV	+0.374	<.001	8	view →
CCRCC	Male	All	+0.139	<.001	6	view →
PDAC	Male	III,IV	+0.252	.012	4	view →
OV	All	All	+0.416	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ZMYND8–LSCC

Open the LSCC breakdown →